Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | BPTF | Q12830 | 1/20 | 0.36 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.36 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21623960 | 0.90 | MKNK1 (0.35) | MKNK1MKNK2ALDH1A1P4HTM | |
| SCHEMBL26237112 | 0.82 | MKNK1 (0.32) | MKNK1MKNK2P4HTM | |
| SCHEMBL23072001 | 0.79 | CYP1A2 (0.44) | CYP1A2BPTFALDH1A1CHRNB2CHRNA4 | |
| SCHEMBL24385685 | 0.78 | PANK3 (0.36) | MKNK1MKNK2P4HTM | |
| SCHEMBL24240290 | 0.75 | MKNK1 (0.34) | MKNK1MKNK2P4HTM | |
| SCHEMBL11181015 | 0.75 | SCD (0.42) | CYP1A2BPTFCHRNB2CHRNA4KMT2A | |
| SCHEMBL31556859 | 0.74 | CYP1A2 (0.38) | CYP1A2BPTFALDH1A1CHRNB2CHRNA4 | |
| SCHEMBL15542949 | 0.74 | CYP1A2 (0.38) | CYP1A2BPTFALDH1A1CHRNB2CHRNA4 | |
| SCHEMBL24385535 | 0.72 | STING1 (0.47) | CYP1A2BPTF | |
| SCHEMBL19402220 | 0.71 | MAP4K4 (0.42) | CYP1A2MKNK1MKNK2ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112424197-B | Difluoromethyl-phenyltriazoles as modulators of GABA receptors | 勃林格殷格翰国际公司 | 2025-04-22 | — | — | CN | disclosed |
| US-20230286946-A1 | DIFLUOROMETHYL-PYRIDIN-2-YL TRIAZOLES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-09-14 | — | — | US | disclosed |
| US-20230286946-A1 | DIFLUOROMETHYL-PYRIDIN-2-YL TRIAZOLES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-09-14 | — | — | US | disclosed |
| EP-3823967-B1 | DIFLUOROMETHYL-PHENYL TRIAZOLES AS GABA RECEPTOR MODULATORS | BOEHRINGER INGELHEIM INT (DE) | 2022-08-31 | — | — | EP | disclosed |
| EP-3992188-A1 | DIFLUOROMETHYL-PYRIDIN-2-YL TRIAZOLES | Boehringer Ingelheim International GmbH (DE) | 2022-05-04 | — | — | EP | disclosed |
| EP-3950683-A1 | DIFLUOROMETHYL-PYRIDIN-2-YL TRIAZOLES | Boehringer Ingelheim International GmbH (DE) | 2022-02-09 | — | — | EP | disclosed |
| EP-3823967-A1 | DIFLUOROMETHYL-PHENYL TRIAZOLES AS GABA RECEPTOR MODULATORS | Boehringer Ingelheim International GmbH (DE) | 2021-05-26 | — | — | EP | disclosed |
| US-20210147393-A1 | DIFLUOROMETHYL-PHENYL TRIAZOLES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-05-20 | — | — | US | disclosed |
| US-20210147393-A1 | DIFLUOROMETHYL-PHENYL TRIAZOLES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-05-20 | — | — | US | disclosed |
| US-10941137-B2 | Difluoromethyl-phenyl triazoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-03-09 | — | — | US | disclosed |
| US-10941137-B2 | Difluoromethyl-phenyl triazoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-03-09 | — | — | US | disclosed |
| CN-112424197-A | Difluoromethyl-phenyl triazoles as GABA receptor modulators | 勃林格殷格翰国际公司 | 2021-02-26 | — | — | CN | disclosed |
| WO-2020016443-A1 | DIFLUOROMETHYL-PHENYL TRIAZOLES AS GABA RECEPTOR MODULATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10941137-B2 | Difluoromethyl-phenyl triazoles | GABRA5, GABRB1, GABRA1 | CYP1A2 164/4885BPTF 2265/4885MKNK1 3213/4885 |
| US-20230286946-A1 | DIFLUOROMETHYL-PYRIDIN-2-YL TRIAZOLES | GABRA5, GABRA3, GABRA2 | CYP1A2 150/4885BPTF 2285/4885MKNK1 3089/4885 |
| US-20210147393-A1 | DIFLUOROMETHYL-PHENYL TRIAZOLES | GABRA5, GABRB1, GABRA1 | CYP1A2 157/4885BPTF 2248/4885MKNK1 3228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.